✦ LIBER ✦

Successful treatment of resistant visceral leishmaniasis with liposomal amphotericin B

✍ Scribed by P.C. Gokhale; N.A. Kshirsagar; M.U. Khan; S.K. Pandya; Y.V. Meisheri; C.P. Thakur; C.B. Choudhary

Publisher: Elsevier Science
Year: 1994
Tongue: English
Weight: 158 KB
Volume: 88
Category: Article
ISSN: 0035-9203
DOI: 10.1016/0035-9203(94)90309-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment with liposomal amphotericin B

Treatment with liposomal amphotericin B of a child affected with drug-resistant visceral leishmaniasis

✍ R Giacchino; G Giambartolomei; L Tasso; A Timitilli; E Castagnola; M Brisigotti; 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 149 KB

Apparently successful treatment of two c

Apparently successful treatment of two cases of post kala-azar dermal leishmaniasis with liposomal amphotericin B

✍ F.A. Hashim; E.A.G. Khalil; A. Ismail; A.M.El Hassan 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 152 KB

Dose-ranging studies on liposomal amphot

Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis

✍ P.V. Bodhe; R.N. Kotwani; B.G. Kirodian; A.V. Pathare; A.K. Pandey; C.P. Thakur; 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 537 KB

Efficacy and tolerability of liposomal amphotericin B (LAMP-LRC-1; developed in India by the Liposome Clinical Pharmacology Centre, Mumbai, and the Liposome Research Centre, New Delhi) were assessed in 63 patients suffering from visceral leishmaniasis at centres in Mumbai and Pama. Patients were tre

Successful treatment of mycotic hepatic

Successful treatment of mycotic hepatic artery pseudoaneurysms with arterial reconstruction and liposomal amphotericin B

✍ Rudich, Steven M. ;Kinkhabwala, Milan M. ;Murray, Natalie G. ;See, Darryl M. ;Bu 📂 Article 📅 1998 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 73 KB

A 55-year-old woman developed end-stage liver disease and the hepatorenal syndrome secondary to cryptogenic cirrhosis. Orthotopic liver transplantation was complicated by bile peritonitis, requiring reoperation and eventual placement of an internal biliary stent. On postoperative day 26, hemobilia w

Post-kala-azar dermal leishmaniasis with

Post-kala-azar dermal leishmaniasis with mucosal involvement in a kidney transplant recipient: treatment with liposomal amphotericin B

✍ Roustan; JimÉnez; GutiÉrrez-Solar; Gallego; Alvar; PatrÓN 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 294 KB

Post-kala-azar dermal leishmaniasis (PKDL) is a rare clinical variant of cutaneous leishmaniasis. It is very common in the Indian subcontinent and less frequent in East Africa, but exceptional in the American and European continents. We have observed a case of PKDL in a renal transplant recipient. N

Amphotericin B deoxycholate treatment of

Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases

✍ C.P. Thakur; R.K. Singh; S.M. Hassan; R. Kumar; S. Narain; Ashok Kumar 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 747 KB

Out of 938 parasitologically confirmed patients with visceral leishmaniasis treated with amphotericin B (1 mg/kg bodyweight daily infused in 2 h for 20 days), 935 were cured clinically, 933 parasitologically and 931 ultimately (no relapse within 6 months). Two parasitologically 'not cured' and 4 rel